5.Lazo SH
Cascone T, William Jr WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy M, Carter BW, Federico L, Reuben A, Khan AW, Dejima H, Cruz AF, Parra ER, Solis LM, Fujimoto J, Tran H, Moran C, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein Jr G, Le X, Zhang J, Skoulidis F, Kurie J, Altan M, Lu C, Glisson B, Byers LA, Elamin Y, Mehran RJ, Rice DC, Walsh G, Hofstetter WL, Roth JA, Antonoff M, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison J, Futreal A, Wargo JA, Wistuba II, Swisher SG , Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B
The Phase 2 ACT-AD trial (NCT04491006) in mild-to-moderate Alzheimers disease failed its primary endpoint in June 2022
When youre ready to check out, choose Flex | Pay with HSA/FSA as your payment option
Oxidation of fatty acids also yields NADH that is needed by the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase, to function in the gluconeogenic direction
Nanomedicine 20, 84518479